SCHEMBL7149819

SCHEMBL7149819

Cc1cccc(NS(=O)(=O)CCCCSc2nc3ccccc3s2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
HSD17B10 Q99714 1/20 0.53
SMN1; SMN2 Q16637 6/20 0.50
LMNA P02545 5/20 0.50
MAPT P10636 4/20 0.49
KMT2A Q03164 2/20 0.49
HTT P42858 2/20 0.49
CYP1A2 P05177 4/20 0.48
CYP2C19 P33261 3/20 0.48
IDO1 P14902 1/20 0.48
CYP2D6 P10635 3/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
CYP3A4 P08684 2/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
MEN1 O00255 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
KDM4E B2RXH2 1/20 0.47
GFER P55789 1/20 0.47
CYP2C9 P11712 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7147570 0.97 ALDH1A1 (0.54) ALDH1A1HSD17B10SMN1; SMN2LMNAMAPT
SCHEMBL7149659 0.93 ALDH1A1 (0.59) ALDH1A1HSD17B10SMN1; SMN2LMNAMAPT
SCHEMBL7148116 0.92 ALDH1A1 (0.42) ALDH1A1HSD17B10SMN1; SMN2LMNAMAPT
SCHEMBL7146167 0.89 ALDH1A1 (0.43) ALDH1A1HSD17B10SMN1; SMN2LMNAMAPT
SCHEMBL7144795 0.89 ALDH1A1 (0.56) ALDH1A1HSD17B10SMN1; SMN2LMNAMAPT
SCHEMBL7155045 0.87 ALDH1A1 (0.50) ALDH1A1HSD17B10SMN1; SMN2LMNAMAPT
SCHEMBL7149832 0.87 MAPT (0.45) ALDH1A1SMN1; SMN2LMNAMAPTKMT2A
SCHEMBL7154107 0.86 MAPT (0.52) ALDH1A1HSD17B10SMN1; SMN2LMNAMAPT
SCHEMBL7144757 0.85 ALDH1A1 (0.57) ALDH1A1HSD17B10SMN1; SMN2LMNAMAPT
SCHEMBL7146699 0.84 ALDH1A1 (0.47) ALDH1A1HSD17B10SMN1; SMN2LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642263-B2 Antitumor agents, sulfided benzothiazole derivative containing sulfonamide ICONIX PHARMACEUTICALS INC. 2003-11-04 US disclosed
US-20030176474-A1 Modulators of Rho C activity ICONIX BIOSCIENCES, INC. 2003-09-18 US disclosed
WO-2003043577-A2 MODULATORS OF RHO C ACTIVITY ICONIX PHARMACEUTICALS, INC. (US) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176474-A1 Modulators of Rho C activity RHOC, ARHGDIA, ROCK1 ALDH1A1 2919/4885HSD17B10 2088/4885SMN1; SMN2 3295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.